CBAY CymaBay Therapeutics Inc.

1.91
+0.01  (+1%)
Previous Close 1.9
Open 1.86
Price To Book 0.62
Market Cap 131,218,992
Shares 68,701,043
Volume 397,426
Short Ratio
Av. Daily Volume 2,550,495
Stock charts supplied by TradingView

NewsSee all news

  1. CymaBay Therapeutics Halts Clinical Development of Seladelpar

    NEWARK, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high

  2. CymaBay Therapeutics to Present at Upcoming Investor Conferences

    NEWARK, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

  3. CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    NEWARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high

  4. CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis

    NEWARK, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

  5. CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

    NEWARK, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 planned - to be initiated by Kowa Pharmaceuticals.
Arhalofenate
Gout
Clinical development of Seladelpar discontinued - November 25, 2019.
Seladelpar
Primary biliary cholangitis (PBC)
Clinical development of Seladelpar discontinued - November 25, 2019.
Seladelpar
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. CymaBay Therapeutics Halts Clinical Development of Seladelpar

    NEWARK, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high

  2. CymaBay Therapeutics to Present at Upcoming Investor Conferences

    NEWARK, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

  3. CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    NEWARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high

  4. CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis

    NEWARK, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

  5. CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

    NEWARK, Calif., Oct. 14, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

  6. CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2019

    NEWARK, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced that two abstracts related to its seladelpar development program for the treatment of primary biliary

  7. CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

    NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

  8. CymaBay Therapeutics Announces Departure of Chief Medical Officer

    NEWARK, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients

  9. CymaBay Therapeutics to Present at Upcoming Investor Conferences in September

    NEWARK, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients